medix infusion

Soliris Order Form
(eculizumab)

FAX TO: 972.499.9210

PATIENT INFORMATION

Patient Name: ______________________ DOB: ________ Phone: ______________ Sex: M F Ht: _____ Wt: _____ lbs kg

Primary Language: ______________ Allergies: ______________________________

Patient Preferred Location: ______________________________

DIAGNOSIS & CLINICAL INFORMATION

<ICD 10 CODE REQUIRED>

ICD 10 Code
- D58.8 Other Specified Hereditary Hemolytic Anemias
- D59.3 Hemolytic Uremic Syndrome
- D59.4 Other Non-Autoimmune Hemolytic Anemias (Including Microangiopathic Hemolyticanemia)
- D59.5 Paroxysmal Nocturnal Hemoglobinuria
- D59.8 Other Acquired Heamolytic Anemias

ICD 10 Code
- G36.0 Neuromyelitis Optica
- G70.00 Generalized Myasthenia Gravis, w/o Acute Exacerbation
- G70.01 Generalized Myasthenia Gravis, w/Acute Exacerbation

Other: ______________________

Prescribing Information
Meningococcal document required for all diagnoses. See Pre-Medications and Required Labs by diagnosis below.

REQUIRED: **Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.**
LAB RESULTS: **Include labs to support diagnosis.**

PRESCRIPTION

SOLIRIS	DILUENT VOLUME	FINAL VOLUME
300 mg	30 mL	60 mL
600 mg	60 mL	120 mL
900 mg	90 mL	180 mL
1200 mg	120 mL	240 mL

SOLIRIS (eculizumab)
Administer over at least 35 minutes in adults, not to exceed 2 hours.

PAROXUSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Loading Dose
IV: Infuse 600 mg dose weekly for first 4 weeks followed by 900 mg dose at week 5

Maintenance Dose
IV: Infuse 900 mg dose every 2 weeks for one year

Pre-Medications
- Acetaminophen: 650 mg PO
- Cetirizine: 10 mg PO
- Diphenhydramine: 25 mg PO
- Diphenhydramine: 25 mg IVP

Other: ______________

Required Labs
- Baseline Serum Lactage Dehydrogenase (LHD) Hemoglobin Level
- Documented Meningococcal Vaccine

ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)

Loading Dose
IV: Infuse 900 mg dose weekly for first 4 weeks followed by 1200 mg dose at week 5

Maintenance Dose
IV: Infuse 1200 mg dose every 2 weeks for one year

Pre-Medications
- Acetaminophen: 650 mg PO
- Cetirizine: 10 mg PO
- Diphenhydramine: 25 mg PO
- Diphenhydramine: 25 mg IVP

Other: ______________

Required Labs
- Baseline Serum Lactate Dehydrogenase (LHD) Hemoglobin Level
- Serum Creatinine/eGFR
- Platelet Count
- Plasma Exchange
- Documented Meninococcal Vaccine

GENERALIZED MYASTHENIA GRAVIS (gMG) and NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

Loading Dose
IV: Infuse 900 mg dose weekly for first 4 weeks followed by 1200 mg dose at week 5

Maintenance Dose
IV: Infuse 1200 mg dose every 2 weeks for one year

Pre-Medications
- Acetaminophen: 650 mg PO
- Cetirizine: 10 mg PO
- Diphenhydramine: 25 mg PO
- Diphenhydramine: 25 mg IVP

Other: ______________

Required Labs
- Positive Serologic Test for Anti-AChR Antibodies
- Documented Meningococcal Vaccine

Post Treatment Observations: The patient is observed for 60 minutes following the first administration.

Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

PRESCRIBER INFORMATION

Prescriber Name: ______________________ Signature: ______________________

Date: __________ NPI #: ______________ Specialty: ______________________

Supervising Physician: ______________________________ (If Applicable)

Address: ______________ City: ______________ State: ________ Zip: ________

Contact Name: ____________ Phone: ____________ Fax: ____________ Email: ____________